Hyderabad: A Hyderabad-based biotech start-up, Utopia Therapeutics, has secured a United States patent for its pioneering immunotherapy-based obesity vaccine, marking a significant milestone ...
ANK-203 is a first-in-class anchored immunotherapy designed to unlock the full therapeutic potential of monoclonal antibody CD137 through localized delivery and retentionIn preclinical studies, ...
Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, ...
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...
Over the past years, I have closely followed the evolution of the global oncology industry. What I have observed is steady, structural growth supported by science, policy support, and increasing ...
A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic ...
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...
Obesity and related metabolic disorders such as fatty liver disease and high triglycerides are rising globally, with limited long-term treatment options ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel ...
PLT012 received FDA fast track status for liver cancer, with an ongoing trial evaluating safety and early activity of the CD36-targeting immunotherapy.
The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results